Last SFr.3.33 CHF
Change Today +0.23 / 7.42%
Volume 48.0K
ADXN On Other Exchanges
Symbol
Exchange
ADXN is not on other exchanges.
As of 9:11 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

addex pharmaceuticals ltd (ADXN) Snapshot

Open
SFr.3.09
Previous Close
SFr.3.10
Day High
SFr.3.34
Day Low
SFr.3.04
52 Week High
07/4/14 - SFr.5.24
52 Week Low
05/5/14 - SFr.1.28
Market Cap
33.9M
Average Volume 10 Days
75.4K
EPS TTM
SFr.-1.60
Shares Outstanding
10.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADDEX PHARMACEUTICALS LTD (ADXN)

Related News

No related news articles were found.

addex pharmaceuticals ltd (ADXN) Related Businessweek News

No Related Businessweek News Found

addex pharmaceuticals ltd (ADXN) Details

Addex Therapeutics Ltd., together with its subsidiaries, is engaged in the discovery, development, and commercialization of small-molecule pharmaceutical products for the treatment of human health. The company’s lead products include dipraglurant ADX48621, a metabotropic glutamate receptor (mGluR) 5 negative allosteric modulator that is in Phase IIa clinical trial for the treatment of Parkinson’s disease levodopa-induced dyskinesia; and ADX71149, an mGluR2 positive allosteric modulator (PAM), which is under Phase IIa clinical trial to treat schizophrenia and anxiety. It also develops various preclinical programs comprising GABA-BR PAM for overactive bladder and other disorders; mGluR4 PAM for the treatment of Parkinson’s, multiple sclerosis, and other diseases; GLP1R PAM for type 2 diabetes; and mGluR2 NAM for treating Alzheimer's disease and depression. In addition, the company has discovery programs to identify allosteric modulators, including TrkB PAM for neurodegenerative diseases; and TNFR1 NAM for inflammatory diseases. The company’s product under development also includes ADX71441 for the treatment of alcohol addiction, Charcot-Marie-Tooth disease, and other indications. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGlu2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd. and changed its name to Addex Therapeutics Ltd. in March 2012. Addex Therapeutics Ltd. was founded in 2002 and is headquartered in Geneva, Switzerland.

5 Employees
Last Reported Date: 05/31/14
Founded in 2002

addex pharmaceuticals ltd (ADXN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.358.9K
Compensation as of Fiscal Year 2013.

addex pharmaceuticals ltd (ADXN) Key Developments

Addex Therapeutics Announces Positive Results with ADX71441

Addex Therapeutics announced positive results with ADX71441 (GABAB receptor positive allosteric modulator) in preclinical models of nicotine addiction. The results were generated as part of an ongoing research collaboration with the United States National Institute for Drug Abuse (NIDA). The study with ADX71441 examined its effects on mecamylamine precipitated physical and affective withdrawal signs in mice rendered dependent on chronic nicotine. Compared to saline-infused mice, nicotine-withdrawn mice showed a significant increased anxiety-related response, a significant increase in somatic signs and significant hyperalgesia compared to vehicle controls. Oral treatment with ADX71441 at 1, 3 and 10 mg/kg administered 60 minutes prior to the precipitant, mecamylamine, dose-dependently reversed the somatic signs of withdrawal in nicotine-dependent mice. ADX71441 also reversed hyperalgesia at the high dose of 10 mg/kg. The high dose of ADX71441 alone did not precipitate withdrawal anxiety-like behavior, somatic signs or hyperalgesia in saline-treated mice. Overall these data indicate that ADX71441 could alleviate the physical signs associated with nicotine withdrawal and help patients to achieve smoking cessation.

Addex Therapeutics Ltd. Approves Amendments to the Articles of Association

Addex Therapeutics Ltd. approved the amendments to the Articles of Association, at its 2014 annual general meeting.

Addex Therapeutics Ltd. Announces Board Changes

In accordance with the restructuring of Addex Therapeutics that took place in 2013, the company announced that André J. Mueller, Hoyoung Huh and Oleg Nodelman are not standing for re-election to the board of directors at this annual general meeting to be held on June 27, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXN:SW SFr.3.33 CHF +0.23

ADXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADXN.
View Industry Companies
 

Industry Analysis

ADXN

Industry Average

Valuation ADXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 198.5x
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 192.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADDEX PHARMACEUTICALS LTD, please visit www.addextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.